RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Relmada Therapeutics - Stock

Relmada Therapeutics Stocks 2024

Relmada Therapeutics Stocks

30.1 M

Relmada Therapeutics Dividend yield

Ticker

RLMD

ISIN

US75955J4022

WKN

A2PSZF

In 2024, Relmada Therapeutics had 30.1 M outstanding stocks, a 0% change from the 30.1 M stocks in the previous year.

The Relmada Therapeutics Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2029e30.1
2028e30.1
2027e30.1
2026e30.1
2025e30.1
2024e30.1
202330.1
202229.63
202117.55
202015.59
20196.31
20183.14
20173.02
20162.9
20152.49
20142.49
20131.21
20121.22
20110.82

Relmada Therapeutics Aktienanalyse

What does Relmada Therapeutics do?

Relmada Therapeutics Inc is a biopharmaceutical company specializing in the development of medications for a variety of chronic pain and mental health disorders. The company is headquartered in New York, USA, and was founded in 2004. The history of Relmada Therapeutics Inc began with a focus on the development of NMDA receptor antagonists for the treatment of neuropathic pain. The company's main drug, d-Methadone, has been successfully tested in a Phase IIa clinical study and is now being tested in Phase IIb studies. Relmada Therapeutics Inc's business model is based on the development and commercialization of novel drugs targeting high medical needs. The company has a strong pipeline of pharmaceutical products in various clinical phases that can be used in pain management and mental health promotion. Relmada Therapeutics Inc generates revenue through the sale of patents and the out-licensing of their products to other pharmaceutical companies. In addition, the company pursues partnerships and joint ventures with other companies to further develop and market their products. Relmada Therapeutics Inc operates in three main divisions: pain therapy, mental health, and oncology. In pain therapy, the company has its main products, such as Oral Methadone and LevoCap ER, which help patients alleviate chronic pain. LevoCap ER is a long-acting, non-addictive pain medication that increases effectiveness and safety compared to other opioids. In the mental health field, Relmada Therapeutics Inc has developed QN-19, an overactive NMDA receptor blocker that represents a potential treatment option for depressive disorders. The company has also developed its new technology platform, mGluR2/3 agonists, which can be used in the treatment of anxiety and depression. In the oncology division, the company focuses on the development of innovative cancer treatments. The company is currently developing a new cancer drug that aims to overcome chemotherapy resistance. Relmada Therapeutics Inc is committed to providing innovative solutions to improve and enhance the quality of life for patients. The company relies on a strong research and development platform to develop medications targeting a variety of needs. The company is committed to continuing its research and development to provide innovative solutions that improve the treatment of chronic diseases. Answer: Relmada Therapeutics Inc is a biopharmaceutical company specializing in the development of medications for chronic pain and mental health disorders. The company is headquartered in New York, USA, and has a strong pipeline of pharmaceutical products in various clinical phases. They generate revenue through the sale of patents and partnerships with other companies, and their divisions focus on pain therapy, mental health, and oncology. They aim to provide innovative solutions to improve patient quality of life and continue research and development for better treatment options. Relmada Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Relmada Therapeutics's Shares Outstanding

Relmada Therapeutics's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Relmada Therapeutics’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Relmada Therapeutics’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Relmada Therapeutics’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Relmada Therapeutics Stock

How many stocks are there of Relmada Therapeutics?

The current number of stocks of Relmada Therapeutics is 30.1 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Relmada Therapeutics are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Relmada Therapeutics evolved in recent years?

The number of shares of Relmada Therapeutics has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Relmada Therapeutics as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Relmada Therapeutics?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Relmada Therapeutics pay?

Over the past 12 months, Relmada Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Relmada Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Relmada Therapeutics?

The current dividend yield of Relmada Therapeutics is .

When does Relmada Therapeutics pay dividends?

Relmada Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Relmada Therapeutics?

Relmada Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Relmada Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Relmada Therapeutics located?

Relmada Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Relmada Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Relmada Therapeutics from 6/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/6/2024.

When did Relmada Therapeutics pay the last dividend?

The last dividend was paid out on 6/6/2024.

What was the dividend of Relmada Therapeutics in the year 2023?

In the year 2023, Relmada Therapeutics distributed 0 USD as dividends.

In which currency does Relmada Therapeutics pay out the dividend?

The dividends of Relmada Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Relmada Therapeutics

Our stock analysis for Relmada Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Relmada Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.